Inventor · disambiguated record
William Gaarde
Also filed as: GAARDE WILLIAM · GAARDE WILLIAM A
15 granted patents·25 pending applications·1,233 citations·filing 1998–2012
95Inventor score
Top patents by PatentIndex Score
40 records- 0199US6287860B1Antisense inhibition of MEKK2 expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Sep 11, 2001·334 cites·14 claims
- 0298US7709630B2Antisense modulation of connective tissue growth factor expressionISIS PHARMACEUTICALS INC·Filed 2008·Granted May 4, 2010·131 cites·23 claims
- 0398US6965025B2Antisense modulation of connective tissue growth factor expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Nov 15, 2005·247 cites·11 claims
- 0495US6133246AAntisense oligonucleotide compositions and methods for the modulation of JNK proteinsISIS PHARMACEUTICALS INC·Filed 1999·Granted Oct 17, 2000·262 cites·3 claims
- 0593US6331399B1Antisense inhibition of tert expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Dec 18, 2001·42 cites·32 claims
- 0692US6809193B2Antisense oligonucleotide compositions and methods for the modulation of JNK proteinsISIS PHARMACEUTICALS INC·Filed 2001·Granted Oct 26, 2004·33 cites·2 claims
- 0791US7507810B2Compositions and their uses directed to IL-4R alphaISIS PHARMACEUTICALS INC·Filed 2006·Granted Mar 24, 2009·14 cites·11 claims
- 0888US6448079B1Antisense modulation of p38 mitogen activated protein kinase expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Sep 10, 2002·24 cites·13 claims
- 0987US6133031AAntisense inhibition of focal adhesion kinase expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted Oct 17, 2000·54 cites·29 claims
- 1081US6492171B2Antisense modulation of TERT expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Dec 10, 2002·7 cites·32 claims
- 1175US6140124AAntisense modulation of P38 mitogen activated protein kinase expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted Oct 31, 2000·27 cites·24 claims
- 1272US8076306B2Compositions and their uses directed to hepcidinMONIA BRETT P·Filed 2007·Granted Dec 13, 2011·1 cites·30 claims
- 1370US6221850B1Antisense oligonucleotide compositions and methods for the modulation of JNK proteinsISIS PHARMACEUTICALS INC·Filed 1998·Granted Apr 24, 2001·23 cites·23 claims
- 1466US6168950B1Antisense modulation of MEKK1 expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted Jan 2, 2001·19 cites·23 claims
- 1563US2005059629A1Antisense modulation of connective tissue growth factor expressionISIS PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 1661US6080546AAntisense modulation of MEKK5 expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted Jun 27, 2000·15 cites·20 claims
- 1761US2005130924A1Antisense inhibition via RNAse H-independent reduction in mRNAFiled 2004·Application pending·0 cites
- 1861US2005227938A1Antisense modulation of TFAP2C expressionBENNETT C F·Filed 2004·Application pending·0 cites
- 1959US2004063129A1Antisense modulation of PPAR-delta expressionFiled 2003·Application pending·0 cites
- 2056US2005267063A1Antisense modulation of p70 S6 kinase expressionBENNETT C F·Filed 2005·Application pending·0 cites
- 2155US2005153925A1Compositions and their uses directed to transferasesFiled 2004·Application pending·0 cites
- 2254US2003224514A1Antisense modulation of PPAR-delta expressionISIS PHARMACEUTICALS INC·Filed 2002·Application pending·0 cites
- 2353US2004192628A1Antisense modulation of focal adhesion kinase expressionFiled 2003·Application pending·0 cites
- 2452US2004033976A1Antisense modulation of mekk3 expressionFiled 2001·Application pending·0 cites
- 2552US2012184031A1Antisense inhibition via rnase h-independent reduction in mrnaMONIA BRETT P·Filed 2012·Application pending·0 cites
- 2651US2003176383A1Antisense modulation of p38 mitogen activated protein kinase expressionFiled 2002·Application pending·0 cites
- 2751US2004171566A1Antisense modulation of p38 mitogen activated protein kinase expressionFiled 2003·Application pending·0 cites
- 2850US2003144242A1Antisense modulation of MEKK4 expressionFiled 2003·Application pending·0 cites
- 2949US2004029823A1Antisense oligonucleotide compositions and methods for the modulation of JNK proteinsFiled 2003·Application pending·0 cites
- 3049US2004097446A1Modulation of checkpoint kinase 1 expressionISIS PHARMACEUTICALS INC·Filed 2002·Application pending·0 cites
- 3148US2001034329A1Antisense modulation of focal adhesion kinase expressionFiled 2001·Application pending·0 cites
- 3248US2004014050A1Antisense modulation of EDG8 expressionISIS PHARMACEUTICALS INC·Filed 2002·Application pending·0 cites
- 3346US2003125274A1Antisense modulation of human collapsin response mediator protein 2 expressionISIS PHARMACEUTICALS INC·Filed 2001·Application pending·0 cites
- 3445US2005215504A1Antisense modulation of sterol regulatory element-binding protein-1 expressionBENNETT C F·Filed 2004·Application pending·0 cites
- 3544US2006019920A1Antisense modulation of MEKK4 expressionBENNETT C F·Filed 2005·Application pending·0 cites
- 3643US2012115930A1Compositions and their uses directed to hepcidinMONIA BRETT P·Filed 2011·Application pending·0 cites
- 3743US2006160758A1Antisense modulation of CD40 ligand expressionBENNETT C F·Filed 2005·Application pending·0 cites
- 3842US2011172296A1Modulation of transforming growth factor-beta 1 expressionBENNETT C FRANK·Filed 2011·Application pending·0 cites
- 3939US2003212018A1Antisense modulation of mekk2 expressionFiled 2001·Application pending·0 cites
- 4038US2011213011A1Modulation of smad3 expressionDEAN NICHOLAS M·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when William Gaarde files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →